RenovoRx (RNXT) highlighted its accelerating commercial momentum at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026, raising its full-year 2026 revenue guidance to $3.75 million to $4.25 million—up from its prior range of $3 million to $4 million. The company reported Q2 2026 revenue of $909,000, marking an 115% year-over-year increase and a 61% sequential rise from Q1 2026. First-half 2026 revenue reached $1.5 million, a 138% jump from the same period in 2025. These figures reflect a sales infrastructure now in place, following a 2025 baseline of $1 million—a stark contrast to its pre-launch revenue trajectory.
RenovoRx’s commercial growth is underpinned by its FDA-cleared RenovoCath, a device using the Trans-Arterial Micro-Perfusion (TAMP) system to deliver targeted therapy for pancreatic cancer. The company’s active clinical sites expanded from six at year-end 2025 to 11 by Q1 2026, reaching 21 by mid-August 2026, with a year-end target of 35–36 centers. Out of a total pipeline of 63 centers, 15 are expected to transition from Phase III trials to full commercial adoption by the second half of 2026.
The company’s market penetration ambitions are substantial: with an estimated $400 million peak sales opportunity based on a 10% penetration rate of the ~7,000-patient addressable pancreatic cancer market. The U.S. market alone is dominated by 200 centers treating non-metastatic tumors, with 100 hospitals handling the majority of cases and 50 hospitals accounting for 50%–60% of cases.
RenovoRx’s pricing model reflects its premium positioning: the RenovoCath unit costs $6,000 to $8,500, though the company anticipates gross margins of 85% and operating margins of 30% at scale. Gross margins have already stabilized at 85%, while the current current ratio of 5.74 underscores its liquidity position.
The company’s clinical pipeline remains robust. Its lead product, RenovoCath, has demonstrated 6-month survival benefits and a 65% reduction in systemic toxicities compared to systemic chemotherapy in prior interim analyses. A peer-reviewed pharmacokinetic sub-study showed a 50% reduction in systemic drug exposure, reinforcing its targeted delivery advantage. The TIGeR-PaC Phase III trial—testing RenovoCath in treatment-naive patients with locally advanced pancreatic cancer—has completed enrollment, with top-line results expected in the second half of 2027. The trial compares eight treatments over four months of RenovoCath to four months of systemic chemotherapy.
RenovoRx’s market capitalization stands at $79 million, with Wall Street analyst price targets ranging from $3 to $14.50. The company’s intellectual property portfolio is extensive: 20 patents in force and 13 pending, with patent protection extending through 2045.
The device’s procedural advantages—performed as an outpatient under conscious sedation—further support its commercial appeal. Patients receive approximately six treatments (though clinical protocols prescribe eight over four months), with operating pressures ranging from 40–60 mmHg in animals to 100–200 mmHg in humans, delivering 100 times the tissue concentration of systemic delivery. The company’s sales force, currently composed of four to five representatives, is expanding to support its growth strategy.
RenovoRx’s rapid commercialization reflects a well-timed execution of its clinical and reimbursement strategies, positioning it to capitalize on the ~18,000–20,000 addressable patients in the pancreatic cancer market—with metastatic cases estimated to be roughly twice the size of the locally advanced segment.
